Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

79.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 973
Open 79.18
Bid (Size) 78.81 (9)
Ask (Size) 78.85 (7)
Prev. Close 79.18
Today's Range 79.18 - 79.18
52wk Range 60.47 - 79.25
Shares Outstanding N/A
Dividend Yield 1.17%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding oncology, biopharmaceuticals, rare disease portfolios, and launching 20 new... 
Via Benzinga
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
From AstraZeneca
Via Business Wire

Performance

YTD
+15.76%
+15.76%
1 Month
+12.90%
+12.90%
3 Month
+21.74%
+21.74%
6 Month
+23.18%
+23.18%
1 Year
+6.11%
+6.11%

More News

Read More
Large Cap Biopharmaceuticals Performance
Via Talk Markets
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Via Benzinga
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
From AstraZeneca
Via Business Wire
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
Via Benzinga
Exposures COVID-19
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Blue-Chip Stocks to Protect Your Wealth as the Economy Slows
Via InvestorPlace
Topics Economy
Exposures Economy
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Via Benzinga
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead
Via The Motley Fool
Catalyst's New CEO Has Big Ideas For The Small Biotech
Via Investor's Business Daily
3 Biotech Stocks to Sell in May Before They Crash & Burn
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Via Benzinga
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Via Benzinga
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Via FinancialNewsMedia
AstraZeneca Pulls Plug On Vaxzevria COVID-19 Vaccine Amid Surplus of Updated Vaccines
Via Benzinga
Exposures COVID-19
7 Stocks to Buy Before the Next ‘Great Reset’ Begins in 2024
Via InvestorPlace
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Top Analyst Reports For AstraZeneca, Qualcomm & FedEx
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.